Who are TACALCITOL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infuvite Adult, Hectorol, Zemplar, Dovonex, Calcijex, Zemplar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tacalcitol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TACALCITOL — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACALCITOL (TACALCITOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tacalcitol. Area: Immunology.

phase 3 tacalcitol Vitamin D3 receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

TACALCITOL (TACALCITOL). TACALCITOL works by binding to the Vitamin D3 receptor, which helps to reduce inflammation and modulate the immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TACALCITOL TARGET	TACALCITOL		phase 3	tacalcitol	Vitamin D3 receptor
Infuvite Adult	Colecalciferol	Novartis	marketed	Vitamin D	Vitamin D3 receptor	2000-01-01
Hectorol	DOXERCALCIFEROL	Sanofi	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1999-01-01
Zemplar	PARICALCITOL	AbbVie	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1998-01-01
Dovonex	CALCIPOTRIENE		marketed	Vitamin D Analog [EPC]	Vitamin D3 receptor	1993-01-01
Calcijex	CALCITRIOL	Esjay Pharma	marketed	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Zemplar	Zemplar	Danderyd Hospital	marketed		Vitamin D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-07 — Dovonex · 8263580 · Formulation · US

Sponsor landscape (tacalcitol class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TACALCITOL — Competitive Intelligence Brief. https://druglandscape.com/ci/tacalcitol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing